MedPath

Metoclopramide

Generic Name
Metoclopramide
Brand Names
Gimoti, Reglan
Drug Type
Small Molecule
Chemical Formula
C14H22ClN3O2
CAS Number
364-62-5
Unique Ingredient Identifier
L4YEB44I46

Overview

Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980.

Background

Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980.

Indication

Metoclopramide in the oral tablet form is used for symptomatic treatment of both acute and recurrent diabetic gastroparesis, in addition to the treatment of gastroesophageal reflux disease (GERD) in patients who have failed to respond to traditional therapy. A nasal spray formulation is also indicated to treat adults with acute, recurrent diabetic gastroparesis. In the intravenous injection form, it is indicated for the above conditions as well as for the prevention of vomiting that may follow emetogenic chemotherapy or nausea and vomiting after surgery. Intravenous metoclopramide facilitates intubation of the small bowel and stimulates gastric emptying and barium flow in patients who require radiological examination of the stomach or small intestine. In some cases, the delay of gastrointestinal emptying interferes with the radiographic visualization of the gastrointestinal tract, and metoclopramide is used to facilitate emptying in these cases, allowing for adequate diagnostic visualization. Some off-label uses of metoclopramide include the management of radiation-induced nausea and vomiting, gastric bezoars, intractable hiccups, and migraine pain.

Associated Conditions

  • Chemotherapy-Induced Nausea and Vomiting
  • Diabetic Gastroparesis
  • Dyspepsia
  • Flatulence
  • Gastroesophageal Reflux
  • Gastroparesis
  • Hiccups
  • Hyperacidity
  • Migraine
  • Nausea and vomiting
  • Post Operative Nausea and Vomiting (PONV)
  • Radiation-Induced Nausea and Vomiting
  • Acute, recurrent Diabetic Gastroparesis
  • Gastric bezoar

FDA Approved Products

Metoclopramide
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/02/14
NDC:70518-1193
Metoclopramide
Manufacturer:Medical Purchasing Solutions, LLC
Route:INTRAMUSCULAR, INTRAVENOUS
Strength:5 mg in 1 mL
Approved: 2023/05/02
NDC:71872-7265
Metoclopramide
Manufacturer:Preferred Pharmaceuticals Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2023/08/04
NDC:68788-7930
Metoclopramide
Manufacturer:American Health Packaging
Route:ORAL
Strength:10 mg in 1 1
Approved: 2022/10/21
NDC:60687-631
Metoclopramide
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/02/13
NDC:70518-0669

Singapore Approved Products

METOCLOPRAMIDE TABLET 10 mg
Manufacturer:PT ACTAVIS INDONESIA
Form:TABLET
Strength:10 mg
Online:Yes
Approved: 1989/05/12
Approval:SIN02804P
EMELIV TABLET 10 mg
Manufacturer:XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD
Form:TABLET
Strength:10 mg
Online:Yes
Approved: 1989/06/17
Approval:SIN03435P
METOCLOPRAMIDE SYRUP 5 mg/5 ml
Manufacturer:SUNWARD PHARMACEUTICAL PRIVATE LIMITED, SUNWARD PHARMACEUTICAL SDN BHD
Form:SYRUP
Strength:5 mg/5 ml
Online:Yes
Approved: 1989/06/16
Approval:SIN03349P
METOCLOPRAMIDE INJECTION BP 5 mg/ml
Manufacturer:PFIZER (PERTH) PTY LTD
Form:INJECTION
Strength:5 mg/ml
Online:Yes
Approved: 1990/11/14
Approval:SIN05202P
PULIN FILM-COATED TABLET 10 mg
Manufacturer:Y S P INDUSTRIES (M) SDN BHD
Form:TABLET, FILM COATED
Strength:10 mg
Online:Yes
Approved: 1998/12/22
Approval:SIN10581P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath